Clinical trials · New Jersey
Small Cell Lung Cancer clinical trials in New Jersey
We’re tracking 128 recruiting small cell lung cancer studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hackensack, New JerseyAges 19 years+ - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Hackensack, New JerseyAges 18 years+ - NCT07388524RecruitingPhase 3
Testing atezolizumab after surgery for early stage lung cancer
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Brick, New JerseyAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Hackensack, New JerseyAges 18 years+ - NCT07659782RecruitingPhase 2
Study of VS-7375 for KRAS G12D lung cancer
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
East Brunswick, New JerseyAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
East Brunswick, New JerseyAges 18 years+ - NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
East Brunswick, New JerseyAges 18 years+ - NCT07783477RecruitingPhase 1
Armored CAR T cells for DLL3 positive cancers
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
Montvale, New JerseyAges 18 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This study tests a new PET scanner that may give clearer or more detailed pictures of cancer. It is for people who are already scheduled for a PET-CT scan at Memorial Sloan Kettering, and it could help doctors see cancer more precisely.
Basking Ridge, New JerseyAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
New Brunswick, New JerseyAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Hackensack, New JerseyAges 18 years+ - NCT07625644RecruitingPhase 3
New immunotherapy combination for advanced lung cancer
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
East Brunswick, New JerseyAges 18 years+ - NCT07619339RecruitingPhase 1
Study of tepotinib and ivonescimab for non-small cell lung cancer
This trial tests a combination of two drugs, tepotinib and ivonescimab, for people with a certain type of advanced non-small cell lung cancer that has a change called MET exon 14 skipping. The treatment aims to shrink tumors or slow their growth.
Basking Ridge, New JerseyAges 18 years+ - NCT07594522RecruitingPhase 1/Phase 2
Ivonescimab with Radiation for Early Lung Cancer
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
Basking Ridge, New JerseyAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Edison, New JerseyAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
East Brunswick, New JerseyAges 18–99 - NCT07535437RecruitingPhase 1/Phase 2
New Drug Combination for Advanced Lung Cancer After Previous Treatment
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
Basking Ridge, New JerseyAges 18 years+ - NCT07535463RecruitingPhase 1/Phase 2
Ivonescimab, chemotherapy, and radiation for lung cancer with brain tumors
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
Basking Ridge, New JerseyAges 18 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
Hackensack, New JerseyAges 18 years+ - NCT07476287RecruitingPhase 2
Study of PF08634404 plus chemo for transformed small cell lung cancer
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
Basking Ridge, New JerseyAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
East Brunswick, New JerseyAges 18 years+ - NCT07428044RecruitingPhase 2
Trastuzumab Deruxtecan for HER2-mutant lung cancer before surgery
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
Basking Ridge, New JerseyAges 18 years+ - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Mullica Hill, New JerseyAges 18 years+ - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Basking Ridge, New JerseyAges 18 years+
Where these studies are running in New Jersey
Institutions with a site for the recruiting small cell lung cancer studies listed above.
- Memorial Sloan Kettering Bergen · 9 studies
- Memorial Sloan Kettering Monmouth · 9 studies
- Memorial Sloan Kettering Basking Ridge · 8 studies
- Astera Cancer Care · 3 studies
- Hackensack University Medical Center · 3 studies
- START New Jersey · 3 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 2 studies
- Capital Health Medical Center - Hopewell
What taking part in a small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Small Cell Lung Cancer trials in other states
Common questions
- Are there small cell lung cancer clinical trials in New Jersey?
- Yes. We're currently tracking 128 recruiting small cell lung cancer studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung cancer study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung cancer studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.